Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a single-center, single-period, single-dose, open-label, non-randomized study to
assess the mass balance recovery, metabolite profile and metabolite identification of 14C-
labelled rencofilstat ([14C] CRV431). It is planned to enroll 6 healthy male subjects in a
single group. Each subject will receive a single 225 mg oral dose of [14C] CRV431 self-micro
emulsifying drug delivery system (SMEDDS) oral emulsion.